Physician profile
Lauren F Streicher
NPI 1609832872
$47,954.57
in general payments reported to CMS, 2019-2025
8 companies · $24K in 2025
The $24K reported for 2025 was more than what 98% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,994 · 2020: $4,286 · 2022: $7,379 · 2023: $6,382 · 2024: $2,401 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,400 · Travel and Lodging: $3,940 · Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,529.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,400.00 |
| Travel and Lodging | $3,939.88 |
| Food and Beverage | $1,426.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21,264.15 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $10,910.69 | 2023-2025 | |
| Pfizer INC. | $7,822.97 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $7,120.64 | 2023-2025 | Orgovyx, Myfembree |
| Therapeuticsmd, INC. | $339.89 | 2019 | |
| Amag Pharmaceuticals, INC. | $241.90 | 2019 | |
| Novo Nordisk INC | $129.93 | 2023 | |
| Myovant Sciences INC. | $124.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Streicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.